BAM
NRIX icon

Blueshift Asset Management’s Nurix Therapeutics NRIX Stock Holding History

Blueshift Asset Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-8,617
Closed -$258K – 1116
2021
Q3 		$258K Buy
+8,617
New +$266K 0.01% 866

Other funds holding NRIX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Blueshift Asset Management's NRIX Position: Q4 2021 in Review

Blueshift Asset Management sold out of Nurix Therapeutics (NRIX) in Q4 2021, closing a stake of 8,617 shares — an estimated $258K sold.

Blueshift Asset Management first reported a position in NRIX in Q3 2021 and held it in 1 quarter. The position peaked at $258K in Q3 2021. 125 funds tracked by Wall St. Rank hold NRIX as of Q4 2021.

  • Blueshift Asset Management reported no remaining Nurix Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Blueshift Asset Management sold 8,617 Nurix Therapeutics shares in Q4 2021, an estimated $258K.
  • Blueshift Asset Management first reported a position in Nurix Therapeutics in Q3 2021 and held it in 1 quarter.
  • Blueshift Asset Management's Nurix Therapeutics position peaked at $258K in Q3 2021.
  • 125 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q4 2021.

Based on Blueshift Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.